Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy

Cancer

Volumn 72, Issue 11 S, 1993, Pages 3495-3501

  Capizzi, Robert L, ^a   Scheffler, Barbara J ^a   Schein, Philip S ^a  

^a NONE   (United States)

Author keywords

Amifostine; bone marrow protection; bone marrow transplantation; chemoprotection; Ethyol; WR 2721

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; AMIFOSTINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTINEOPLASTIC ACTIVITY; ATOMIC WARFARE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HOSPITALIZATION; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; NONHUMAN; ORGAN PRESERVATION; OVARY CARCINOMA; PRIORITY JOURNAL; RADIATION PROTECTION;

AMIFOSTINE; ANIMAL; ANTINEOPLASTIC AGENTS; BONE MARROW; COLONY-STIMULATING FACTORS; HEMATOPOIETIC STEM CELLS; HUMAN;

EID: 0027381310     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19931201)72:11+<3495::AID-CNCR2820721617>3.0.CO;2-B     Document Type: Article

References (27)

1. Differential chemoprotection of normal and malignant tissues
2. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine
3. The role of Amifostine in radiotherapy and/or chemotherapy
4. Treatment of tumours with the combination of Amifostine and Cis‐Dichlorodiammineplatinum (II) or cyclophosphamide
5. Radiation protectors: the unexpected benefits
6. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S‐2‐(3‐Aminopropylamino)‐ethylphosphorotioic acid
7. Clinical experiences with a chemical radioprotector in tumor radiotherapy: Amifostine
8. Uptake of WR‐2721 derivatives by cells in culture: identification of the transported form of the drug
9. Radioprotection of cells in culture by WR‐2721 and derivatives: form of the drug responsible for protection
10. Alkaline phosphatase promotes radioprotection and accumulation of WR‐1065 in V79‐171 cells incubated in medium containing WR‐2721
11. The modification of melphalan toxicity in tumor bearing mice by S‐2‐(3‐aminopropylamino)‐ethylphosphorothioic acid (WR‐2721)
12. In vitro study on the antioxidant activities of amifostine (WR‐2721)
13. Free radical repair mechanisms and interaction of glutathione and vitamins C and E
14. Interaction of cultured mammalian cells with WR‐2721 and its thiol WR‐1065: implications for mechanisms of radioprotection
15. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR‐2721
16. Protection and potentiation of nitrogen mustard cytotoxicity by WR‐2721
17. WR‐2721 protects against the hematologic toxicity of cyclophosphamide: a controlled Phase II Trial
18. A randomized trial of cyclophosphamide and cisplatin ± WR‐2721 in the treatment of advanced epithemial ovarian cancer
19. Amifostine (WR‐2721) shortens the engraftment period of 4‐HC purged bone marrow in breast cancer patients receiving high‐dose chemotherapy with autologous bone marrow support (ABMS)
20. Amifostine (WR‐2721) shortens the engraftment time of 4‐hydroperoxycyclophosphamide (4‐HC) purged bone marrow in lymphoma patients receiving high dose chemotherapy (HDC) with autologous bone marrow support (ABMS)
21. WR‐2721 and high‐dose cisplatin: an active combination in the treatment of metastatic melanoma
22. Cisplatin neuropathy: risk factors, prognosis and protection by WR‐2721
23. Postirradiation treatment with granulocyte colony‐stimulating factor and preirradiation WR‐2721 administration synergize to enhance hemopoietic reconstitution and increase survival
24. Hypocalcemia and inhibition of parathyroid hormone Secretion after administration of WR‐2721 (a radioprotective and chemoprotective agent)